Business
Viridian Therapeutics Prepares for Transformational 2026
- Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30,...
About this update from Viridian Metals Inc
[{"type":"text","content":"Viridian Therapeutics Prepares for Transformational 2026\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }\n \n\n\n\n\n - Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track -\n \n\n\n\n - Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively -\n \n\n\n\n - IND submitted for half-life extended FcRn-inhibitor, VRDN-008; healthy volunteer (HV) data expected in 2H 2026 -\n \n\n\n\n - Unveiling new program targeting thyroid-stimulating hormone receptor (TSHR); IND expected Q4 2026 -\n \n\n\n\n - Cash position of approximately $888 million as of October 31, 2025 -\n \n\n\n\n - Company expects its current business plans to be funded through profitability -\n \n\n\n\n\n Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and anticipated catalysts for 2026.\n \n\n “Following another year of strong execution across our portfolio, we enter 2026 positioned for meaningful value-creation and progress,” said Steve Mahoney, President and Chief Executive Officer of Viridian. “The FDA’s acceptance of the veligrotug BLA under Priority Review underscores the need for additional treatment options in TED and reinforces our conviction in veligrotug’s strong clinical profile. Our priorities this year are clear: deliver pivotal topline data for elegrobart in Q1 and Q2, prepare for a potential mid‑year approval and launch of veligrotug, and advance our broader pipeline throughout with disciplined execution to create long-term value for patients and shareholders.”\n \n\n\n IGF‑1R Inhibitor Portfolio for TED Positioned for Transformational Impact in 2026\n \n\n\n\n\n Veligrotug BLA granted Priority Review; Prescription Drug User Fee Act (PDUFA) target date June 30, 2026\n \n\n\n The veligrotug BLA, submitted in October 2025, is supported by positive data from two of t...